LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Vanda Pharmaceuticals Inc

Chiusa

4.78 -0.83

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.75

Massimo

4.94

Metriche Chiave

By Trading Economics

Entrata

-25M

-29M

Vendite

-3.1M

50M

EPS

-0.5

Margine di Profitto

-58.94

Dipendenti

368

EBITDA

-23M

-31M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+242.32% upside

Dividendi

By Dow Jones

Utili prossimi

30 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.2M

263M

Apertura precedente

5.61

Chiusura precedente

4.78

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2025, 20:51 UTC

Utili

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 20:48 UTC

Discorsi di Mercato

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 giu 2025, 19:31 UTC

Discorsi di Mercato

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 giu 2025, 19:19 UTC

Discorsi di Mercato

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 giu 2025, 19:16 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 giu 2025, 18:39 UTC

Discorsi di Mercato
Utili

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 giu 2025, 18:29 UTC

Discorsi di Mercato

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 giu 2025, 18:18 UTC

Discorsi di Mercato

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 giu 2025, 18:16 UTC

Discorsi di Mercato

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 giu 2025, 17:16 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 giu 2025, 17:08 UTC

Utili

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 giu 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 giu 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

27 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

27 giu 2025, 15:59 UTC

Discorsi di Mercato

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 giu 2025, 15:56 UTC

Discorsi di Mercato

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Vanda Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

242.32% in crescita

Previsioni per 12 mesi

Media 16.5 USD  242.32%

Alto 20 USD

Basso 13 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vanda Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.22 / 4.44Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.